United States Opioid Use Disorder Drugs Market to hit US$ 6.1 Billion by 2030 | Top Companies - Mallinckrodt Pharmaceuticals, Hikma Pharmaceuticals Inc, Collegium Pharmaceutical, Inc.

"Global Opioid Use Disorder (OUD) Drugs Market reached US$ 2.9 billion in 2022 and is expected to reach US$ 6.1 billion by 2030 growing with a CAGR of 10.1% during the forecast period 2023-2030." As per DataM intelligence research report

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/opioid-use-disorder-drugs-market?sp

United States: Recent Industry Developments

✅ In November 2025, Indivior PLC launched a long-acting buprenorphine injection for opioid use disorder, providing extended release and reduced dosing frequency to improve patient adherence and outcomes. The therapy targets adults with moderate-to-severe OUD. It reinforces Indivior's leadership in innovative addiction treatment solutions in the U.S.

✅ In October 2025, Braeburn Pharmaceuticals introduced a monthly subcutaneous buprenorphine implant for OUD patients, offering steady plasma levels, reduced diversion risk, and improved treatment retention. The product supports outpatient and clinic-based care. It highlights U.S. innovation in long-acting opioid dependency therapies.

✅ In September 2025, Alkermes, Inc. launched a combination therapy integrating extended-release naltrexone with counseling support for opioid use disorder, aiming to enhance adherence and reduce relapse rates. The therapy is designed for adults with moderate-to-severe OUD. It demonstrates U.S. focus on comprehensive, multi-modal treatment strategies.

✅ In August 2025, Mundipharma expanded its portfolio with a sublingual buprenorphine-naloxone film optimized for rapid onset, patient convenience, and reduced abuse potential. The therapy addresses outpatient and office-based treatment settings. It underscores U.S. investment in safer and more effective OUD medications.

Japan: Recent Industry Developments

✅ In November 2025, Mitsubishi Tanabe Pharma launched a buprenorphine-based therapy for opioid use disorder in Japanese hospitals and clinics, targeting patients with moderate-to-severe dependence and aiming to improve treatment adherence. The therapy provides a controlled-release formulation. It reflects Japan's focus on expanding addiction treatment options.

✅ In October 2025, Chugai Pharmaceutical Co., Ltd. introduced a sublingual buprenorphine-naloxone formulation for OUD, designed to reduce diversion and improve compliance in outpatient settings. The product aligns with Japan's regulatory standards for controlled substances. It highlights Japan's investment in safer and more effective opioid dependency treatments.

✅ In September 2025, Astellas Pharma initiated a clinical study of extended-release naltrexone for opioid use disorder, focusing on relapse prevention and improved patient adherence in Japanese populations. The study supports evidence-based OUD management. It demonstrates Japan's commitment to innovative addiction therapies.

✅ In August 2025, Otsuka Pharmaceutical Co., Ltd. launched a digital adherence monitoring platform for OUD patients, combining telemedicine and medication tracking to optimize treatment outcomes and support clinicians. The system enhances adherence and reduces relapse risk. It underscores Japan's adoption of technology-assisted addiction care solutions.

Opioid Use Disorder Drugs Market: Drivers

The opioid use disorder (OUD) drugs market is witnessing strong growth driven by the rising prevalence of opioid addiction and increasing awareness about the health and social impacts of substance abuse. Medications such as buprenorphine, methadone, and naltrexone are widely used for opioid replacement therapy and relapse prevention, providing clinically effective management options. Growing initiatives by governments and healthcare organizations to combat the opioid crisis are encouraging adoption of pharmacological treatments alongside counseling and rehabilitation programs. Increasing patient awareness, healthcare provider training, and accessibility of treatment centers are further supporting market expansion. Additionally, the societal push for addressing addiction as a medical condition is fostering acceptance of OUD therapies.

Technological advancements in drug formulations, including long-acting injectables, sublingual tablets, and implantable devices, are enhancing treatment adherence and clinical outcomes. Collaborations between pharmaceutical companies, research institutions, and public health agencies are accelerating development of safer and more effective therapies. Rising focus on integrated care models that combine medication with behavioral therapy is expanding treatment options and patient engagement. Government funding, insurance coverage, and supportive policies are facilitating broader market access. With ongoing innovation and heightened global attention on opioid addiction management, the OUD drugs market is poised for sustained growth.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/opioid-use-disorder-drugs-market?sp

Opioid Use Disorder Drugs Market: Major Players

Mallinckrodt Pharmaceuticals, Hikma Pharmaceuticals Inc, Collegium Pharmaceutical, Inc., Braeburn, Inc., Purdue Pharma L.P., Curia Global Inc., EMERGENT, Bristol-Myers Squibb, S.r.l, Alkermes, Inc., Indivior Inc, and among others.

Segment Covered in the Opioid Use Disorder Drugs Market:

By Drug Type
Opioid addiction treatments are categorized into Agonist and Antagonist Drugs. Agonist drugs such as Methadone and Buprenorphine dominate the market due to their proven effectiveness in reducing withdrawal symptoms, while antagonist drugs like Naloxone, Naltrexone, and Nalmefene are widely used for relapse prevention and overdose reversal.

By Route of Administration
The market is segmented into Oral, Parenteral, Sublingual, and Nasal routes. The oral route holds the largest share owing to patient convenience and suitability for long-term maintenance therapy, whereas nasal formulations are gaining attention for rapid emergency intervention.

By Age Group
Based on age, the market covers individuals aged 19 to 39, 40 to 59, and 60 and over. The 19 to 39 age group leads due to higher substance use rates among younger adults, although older populations are showing a gradual rise in opioid dependency cases.

By Distribution Channel
Distribution channels include Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Retail pharmacies dominate due to accessibility and prescription-based sales, while online pharmacies are expanding quickly with the growing adoption of telemedicine and digital prescription services.

Research Process:

Both primary and secondary data sources have been used in the Opioid Use Disorder Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Most Frequently Asked Questions in the Opioid Use Disorder Drugs Market Research Industry:

➠ Who leads the Opioid Use Disorder Drugs industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do Opioid Use Disorder Drugs market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting Opioid Use Disorder Drugs market growth?
➠ What are the dominant sales and distribution strategies in the Opioid Use Disorder Drugs industry?

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=opioid-use-disorder-drugs-market
(Purchase 2 or more Repots and get 50% Discount)

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.